Den europeiske union -
norsk -
EMA (European Medicines Agency)
vipdomet
takeda pharma a/s - alogliptin benzoate, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - vipdomet is indicated in the treatment of adult patients aged 18 years and older with type-2 diabetes mellitus:as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin;in combination with pioglitazone (i. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone;in combination with insulin (i. triple kombinasjon terapi) som et tillegg til diett og trening for å bedre glykemisk kontroll hos pasienter når insulin på en stabil dose og metformin alene ikke gir tilstrekkelig glykemisk kontroll.
Den europeiske union -
norsk -
EMA (European Medicines Agency)
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
Norge -
norsk -
Statens legemiddelverk
hirudoid 3 mg/ g
stada arzneimittel ag - mukopolysakkaridpolysulfat - salve - 3 mg/ g
Norge -
norsk -
Statens legemiddelverk
selukos 25 mg/ ml
mylan healthcare norge as - selendisulfid - sjampo - 25 mg/ ml
Den europeiske union -
norsk -
EMA (European Medicines Agency)
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
Norge -
norsk -
Statens legemiddelverk
klyx 1 mg/ ml / 250 mg/ ml
ferring legemidler as - dokusatnatrium / sorbitol - rektalvæske, oppløsning - 1 mg/ ml / 250 mg/ ml
Norge -
norsk -
Statens legemiddelverk
depo-provera 150 mg/ ml
pfizer as - medroksyprogesteronacetat - injeksjonsvæske, suspensjon - 150 mg/ ml
Norge -
norsk -
Statens legemiddelverk
noskapin 2.2 mg/ ml
orifarm healthcare a/s - noskapinhydrokloridhydrat - mikstur, oppløsning - 2.2 mg/ ml
Norge -
norsk -
Statens legemiddelverk
nycoplus neo-fer 9 mg/ ml
takeda as - jern(ii)fumarat - mikstur, suspensjon - 9 mg/ ml